Fecal microbial transplant (DrugBank: -)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
96 | Crohn disease | 5 |
97 | Ulcerative colitis | 4 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03267238 (ClinicalTrials.gov) | June 16, 2017 | 24/7/2017 | Fecal Microbial Transplantation in Patients With Crohn's Disease | Fecal Microbial Transplantation in Patients With Crohn's Disease | Crohn Disease | Biological: Fecal Microbial Transplantation | Stony Brook University | NULL | Active, not recruiting | 7 Years | N/A | All | 9 | Early Phase 1 | United States |
2 | JPRN-UMIN000025846 | 2017/02/01 | 01/02/2017 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | ulcerative colitis, Crohn's disease | Administration of the fecal material from healthy donors to patients after taking three kinds of antibiotics (Amoxicillin, fosmycin, metronidazole) for two weeks | Juntendo university school of medicineDepartment of gastroenterology | NULL | Recruiting | 16years-old | Not applicable | Male and Female | 60 | Not selected | Japan | |
3 | JPRN-jRCTs031180415 | 01/02/2017 | 22/03/2019 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) | AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults). FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. A-FMT arm : Patient undergoes FMT two days after AFM therapy. | Ishikawa Dai | NULL | Recruiting | >= 6age old | Not applicable | Both | 120 | N/A | Japan |
4 | NCT02272868 (ClinicalTrials.gov) | January 2015 | 16/10/2014 | Fecal Microbial Transplant in Pediatric Crohn's Disease | Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study | Crohn's Disease | Biological: Fecal Microbial transplant;Drug: Normal Saline;Drug: rifaximin+omeprazole+miralax | Seattle Children's Hospital | NULL | Completed | 12 Years | 21 Years | All | 7 | Phase 1;Phase 2 | United States |
5 | NCT01847170 (ClinicalTrials.gov) | May 2013 | 2/5/2013 | Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease | Crohn's Disease | Biological: Fecal Microbial Transplantation | Beth Israel Deaconess Medical Center | The Broad Foundation;Brigham and Women's Hospital | Completed | 18 Years | N/A | All | 22 | Phase 1 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000025846 | 2017/02/01 | 01/02/2017 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | ulcerative colitis, Crohn's disease | Administration of the fecal material from healthy donors to patients after taking three kinds of antibiotics (Amoxicillin, fosmycin, metronidazole) for two weeks | Juntendo university school of medicineDepartment of gastroenterology | NULL | Recruiting | 16years-old | Not applicable | Male and Female | 60 | Not selected | Japan | |
2 | JPRN-jRCTs031180415 | 01/02/2017 | 22/03/2019 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) | AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults). FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. A-FMT arm : Patient undergoes FMT two days after AFM therapy. | Ishikawa Dai | NULL | Recruiting | >= 6age old | Not applicable | Both | 120 | N/A | Japan |
3 | NCT02291523 (ClinicalTrials.gov) | November 2016 | 11/11/2014 | The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis | The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis | Ulcerative Colitis | Biological: Fecal Microbial Transplant | Children's Hospital Los Angeles | NULL | Recruiting | 7 Years | 21 Years | All | 101 | Phase 1 | United States |
4 | NCT03268213 (ClinicalTrials.gov) | November 2013 | 22/3/2016 | Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis | Fecal Microbial Transplantation in Patients With Medication Refractory Clostridium Difficile and/or Ulcerative Colitis or Indeterminate Colitis | Clostridium Difficile Infection;Ulcerative Colitis;Indeterminate Colitis | Biological: Fecal Microbial Transplantation | Stony Brook University | NULL | Active, not recruiting | 7 Years | N/A | All | 12 | Early Phase 1 | United States |